Evidence map›Paper›PMID 40779592›Full record

ArticlePloS one2025

Presymptomatic microRNA-based biomarker signatures for the prognosis of localized radiation injury in mice.

Lucie Ancel, Jules Gueguen, Guillaume Thoër, Jules Marçais, Aïda Chemloul, Bernard Le Guen, Marc Benderitter, Radia Tamarat, Maâmar Souidi, Mohamed Amine Benadjaoud and 1 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucie AncelAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Jules GueguenAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.ORCID https://orcid.org/0000-0003-1891-1665
Guillaume ThoërAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Jules MarçaisAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Aïda ChemloulAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Bernard Le GuenEDF, DPN, 1 place Pleyel, Saint Denis, France.
Marc BenderitterASNR, PSE-SANTE, Fontenay-aux-Roses, France.
Radia TamaratASNR, PSE-SANTE, Fontenay-aux-Roses, France.
Maâmar SouidiAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Mohamed Amine BenadjaoudAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
Stéphane FlamantAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.ORCID https://orcid.org/0000-0003-2295-5943

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The threat of nuclear or radiological events requires early diagnostic tools for radiation induced health effects. Localized radiation injuries (LRI) are severe outcomes of such events, characterized by a latent presymptomatic phase followed by symptom onset ranging from erythema and edema to ulceration and tissue necrosis. Early diagnosis is crucial for effective triage and adapted treatment, potentially through minimally invasive biomarkers including circulating microRNAs (miRNAs), which have been correlated with tissue injuries and radiation exposure, suggesting their potential in diagnosing LRI. In this study, we sought to identify early miRNA signatures for LRI severity prognosis before clinical symptoms appear. Using a mouse model of hindlimb irradiation at 0, 20, 40, or 80 Gy previously shown to lead to localized injuries of different severities, we performed broad-spectrum plasma miRNA profiling at two latency stages (day 1 and 7 post-irradiation). The identified candidate miRNAs were then challenged using two independent mouse cohorts to refine miRNA signatures. Through sparse partial least square discriminant analysis (sPLS-DA), signatures of 14 and 16 plasma miRNAs segregated animals according to dose groups at day 1 and day 7, respectively. Interestingly, these signatures shared 9 miRNAs, including miR-19a-3p, miR-93-5p, miR-140-3p, previously associated with inflammation, radiation response and tissue damage. In addition, the Bayesian latent variable modeling confirmed significant correlations between these prognostic miRNA signatures and day 14 clinical and functional outcomes from unrelated mice. This study identified plasma miRNA signatures that might be used throughout the latency phase for the prognosis of LRI severity. These results suggest miRNA profiling could be a powerful tool for early LRI diagnosis, thereby improving patient management and treatment outcomes in radiological emergency situations.

Indexed as

BiomarkersMicroRNAsRadiation InjuriesRadiation Injuries, ExperimentalAnimalsFemaleGene Expression ProfilingMaleMiceMice, Inbred C57BLPrognosisBiomarkersMicroRNAs

Identifiers

PMID40779592
PMCPMC12333984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.